The regulator approved Opdivo label update offering flexible flat-dosing options every two weeks (240 mg) or every four weeks (480 mg). Opdivo, which is a programmed death-1 (PD-1) inhibitor, was
The drug was tested in the Clareos-1 and Clareos-2 trials, which featured over 1,500 patients, aged nine years and older with moderate-to-severe acne vulgaris. Olumacostat glasaretil was evaluated
The research is led by the Warwick Integrative Synthetic Biology Centre at Warwick’s School of Engineering and the Faculty of Health and Medical Sciences at the University of Surrey. The breakthrough helped to
The European Medicines Agency (EMA) has started an Article 20 referral procedure after reports of inflammatory encephalitis and meningoencephalitis. Seven cases of serious inflammatory brain disorders including encephalitis and meningoencephalitis
The injunction was obtained by Endo’s subsidiaries Par Pharmaceutical and Par Sterile Products (Par) from US District Judge Brian Martinotti. The order will prevent QuVa Pharma from marketing
ZTlido includes non-aqueous adhesive material containing 1.8% lidocaine, which will be applied to a non-woven polyester felt backing and covered with a polyethylene terephthalate (PET) film release liner.
The new independent biotech company, Viela Bio, will get six molecules from MedImmune's early-stage inflammation and autoimmunity programs. Viela Bio, which will get a funding of up to $250m, will
Ozanimod is being developed for the treatment of patients with relapsing forms of multiple sclerosis. Ozanimod is an oral and selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor
The drug is a bispecific antibody that targets the factor IXa- and factor X proteins. Hemlibra has been designed to bind the two proteins, which are needed to
It marks the third approval from the US regulator for the breast cancer treatment in five months. The latest approval allows Eli Lilly to use Verzenio in combination
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.